(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 9.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 41.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.04%.
Niagen Bioscience's revenue in 2026 is $129,084,000.On average, 8 Wall Street analysts forecast NAGE's revenue for 2026 to be $10,525,340,786, with the lowest NAGE revenue forecast at $9,247,455,854, and the highest NAGE revenue forecast at $11,208,198,183. On average, 7 Wall Street analysts forecast NAGE's revenue for 2027 to be $12,487,665,636, with the lowest NAGE revenue forecast at $11,864,152,740, and the highest NAGE revenue forecast at $12,999,610,869.
In 2028, NAGE is forecast to generate $13,880,283,271 in revenue, with the lowest revenue forecast at $12,368,185,373 and the highest revenue forecast at $15,306,133,827.